sucralfate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4106	54182-58-0

Description:

Molecule	Description
Synonyms: sucralfate antepsin carafate sucralfin sucrate sulcrate ulcerlmin ulcogant	A basic aluminum complex of sulfated sucrose. Molecular weight: Formula: None CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

sucralfate
antepsin
carafate
sucralfin
sucrate
sulcrate
ulcerlmin
ulcogant

A basic aluminum complex of sulfated sucrose.

Molecular weight:
Formula: None
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
4	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Oct. 30, 1981	FDA	FOREST LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Vaginal flatulence	83.55	11.52	25	26759	668	56264615
Rheumatoid arthritis	81.81	11.52	40	26744	382564	55882719
Drug ineffective	79.53	11.52	203	26581	918786	55346497
Maternal exposure during pregnancy	77.12	11.52	3	26781	189550	56075733
Gastritis	75.86	11.52	88	26696	34614	56230669
Cholecystitis chronic	66.52	11.52	47	26737	9701	56255582
Proctitis	64.16	11.52	29	26755	2531	56262752
Contraindicated product administered	63.99	11.52	7	26777	186279	56079004
Abdominal pain	53.36	11.52	254	26530	258551	56006732
Hand deformity	51.88	11.52	3	26781	134489	56130794
Female genital tract fistula	51.40	11.52	30	26754	4462	56260821
Angina bullosa haemorrhagica	50.06	11.52	12	26772	132	56265151
Joint swelling	49.82	11.52	39	26745	289761	55975522
Nausea	46.63	11.52	561	26223	763617	55501666
Gastrooesophageal reflux disease	46.22	11.52	114	26670	83143	56182140
Oesophagitis	45.60	11.52	44	26740	14013	56251270
Radiculopathy	45.00	11.52	30	26754	5635	56259648
Glossodynia	42.80	11.52	10	26774	152448	56112835
Gastric ulcer	42.40	11.52	53	26731	22510	56242773
Toxicity to various agents	41.47	11.52	28	26756	224536	56040747
Systemic lupus erythematosus	41.27	11.52	17	26767	180061	56085222
Abdominal pain upper	41.16	11.52	181	26603	178132	56087151
Pericarditis	40.32	11.52	3	26781	108920	56156363
Treatment failure	39.19	11.52	16	26768	170376	56094907
Frequent bowel movements	38.16	11.52	43	26741	16381	56248902
Lower respiratory tract infection	37.71	11.52	5	26779	114789	56150494
Facial asymmetry	37.43	11.52	14	26770	753	56264530
Muscle swelling	36.51	11.52	12	26772	439	56264844
Exposure during pregnancy	36.23	11.52	10	26774	136332	56128951
Vaginal discharge	35.88	11.52	27	26757	6136	56259147
Impaired gastric emptying	35.86	11.52	32	26752	9231	56256052
Dehydration	33.49	11.52	157	26627	158668	56106615
Early satiety	31.90	11.52	13	26771	880	56264403
Cholelithiasis	30.87	11.52	62	26722	39402	56225881
Vulval disorder	30.86	11.52	12	26772	718	56264565
Constipation	30.48	11.52	182	26602	201761	56063522
Colitis	29.55	11.52	63	26721	41748	56223535
Musculoskeletal stiffness	29.39	11.52	19	26765	155988	56109295
Wound	27.41	11.52	16	26768	138788	56126495
Gastrointestinal haemorrhage	27.41	11.52	89	26695	75862	56189421
Drug intolerance	27.20	11.52	53	26731	264765	56000518
Tarsal tunnel syndrome	26.89	11.52	10	26774	529	56264754
Product use issue	26.12	11.52	30	26754	186011	56079272
Hepatic enzyme increased	25.88	11.52	26	26758	171358	56093925
Off label use	25.36	11.52	158	26626	556022	55709261
Therapeutic product effect decreased	25.26	11.52	26	26758	169426	56095857
Diarrhoea	24.56	11.52	433	26351	638074	55627209
Vomiting	24.46	11.52	352	26432	497876	55767407
Completed suicide	24.27	11.52	17	26767	133816	56131467
Weight decreased	23.96	11.52	196	26588	240518	56024765
Gallbladder disorder	23.85	11.52	35	26749	17299	56247984
Colitis ulcerative	23.64	11.52	42	26742	24349	56240934
Oral candidiasis	23.14	11.52	36	26748	18727	56246556
Genotype drug resistance test positive	22.67	11.52	8	26776	364	56264919
Intentional overdose	22.29	11.52	3	26781	68114	56197169
Haematemesis	22.27	11.52	45	26739	28713	56236570
Product dose omission issue	22.17	11.52	170	26614	204583	56060700
Oesophageal stenosis	21.75	11.52	15	26769	2978	56262305
Infusion related reaction	21.29	11.52	42	26742	208889	56056394
General physical health deterioration	21.18	11.52	30	26754	169980	56095303
Movement disorder	21.16	11.52	35	26749	19163	56246120
Discomfort	20.84	11.52	22	26762	141739	56123544
Arthropathy	20.63	11.52	40	26744	200235	56065048
Alopecia	20.03	11.52	72	26712	293386	55971897
Purpura senile	19.92	11.52	8	26776	521	56264762
Paranoia	19.80	11.52	25	26759	10719	56254564
Rectal haemorrhage	19.12	11.52	53	26731	41414	56223869
Haemoglobin decreased	19.02	11.52	119	26665	134018	56131265
Cellulitis	18.74	11.52	78	26706	74871	56190412
Urinary tract infection	18.39	11.52	185	26599	240328	56024955
Liver abscess	18.26	11.52	13	26771	2713	56262570
Blister	18.24	11.52	15	26769	108872	56156411
Drug abuse	17.88	11.52	5	26779	67605	56197678
Blood magnesium decreased	17.84	11.52	25	26759	11849	56253434
Migraine	17.69	11.52	85	26699	86712	56178571
Faeces discoloured	17.43	11.52	30	26754	16966	56248317
Therapeutic product effect incomplete	17.28	11.52	15	26769	106016	56159267
Blood alkaline phosphatase increased	17.20	11.52	49	26735	38896	56226387
Hallucination, auditory	16.92	11.52	24	26760	11500	56253783
Biliary dyskinesia	16.66	11.52	12	26772	2551	56262732
Helicobacter infection	16.64	11.52	7	26777	73261	56192022
Haematochezia	16.46	11.52	52	26732	43666	56221617
Flatulence	16.46	11.52	42	26742	31246	56234037
Anaemia	15.99	11.52	196	26588	267315	55997968
Muscle spasms	15.95	11.52	116	26668	137255	56128028
Pancreatic enzyme abnormality	15.80	11.52	3	26781	9	56265274
Gallbladder injury	15.72	11.52	9	26775	1291	56263992
Memory impairment	15.69	11.52	82	26702	86475	56178808
Vestibular disorder	15.56	11.52	9	26775	1316	56263967
Upper respiratory tract infection	14.66	11.52	70	26714	71218	56194065
Chest pain	14.50	11.52	146	26638	189651	56075632
Dysphagia	14.42	11.52	77	26707	81870	56183413
Hiatus hernia	14.33	11.52	30	26754	19622	56245661
Vascular rupture	14.31	11.52	9	26775	1531	56263752
Rash	13.86	11.52	159	26625	492888	55772395
Oesophageal ulcer	13.51	11.52	13	26771	4126	56261157
Peptic ulcer	13.49	11.52	13	26771	4131	56261152
Resorption bone increased	13.39	11.52	8	26776	1242	56264041
Ulcer haemorrhage	13.29	11.52	12	26772	3513	56261770
Burning sensation	13.22	11.52	52	26732	48644	56216639
Pancreatitis	12.94	11.52	49	26735	45031	56220252
Gastric haemorrhage	12.85	11.52	15	26769	5935	56259348
Blood pressure diastolic increased	12.82	11.52	18	26766	8543	56256740
Ocular neoplasm	12.81	11.52	5	26779	302	56264981
Drug interaction	12.67	11.52	54	26730	209701	56055582
Psoriatic arthropathy	12.64	11.52	10	26774	73998	56191285
Crepitations	12.47	11.52	16	26768	6968	56258315
Hyperacusis	12.47	11.52	9	26775	1919	56263364
Platelet count decreased	12.44	11.52	90	26694	106293	56158990
Infusion site swelling	12.38	11.52	17	26767	7904	56257379
Depression	12.09	11.52	135	26649	179982	56085301
Angiodysplasia	12.08	11.52	5	26779	352	56264931
Overdose	11.91	11.52	20	26764	105810	56159473
Lithiasis	11.85	11.52	3	26781	42	56265241
Back pain	11.76	11.52	168	26616	237002	56028281
Psychotic disorder	11.75	11.52	31	26753	23527	56241756

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Gastrointestinal haemorrhage	47.01	12.02	104	12850	82445	31601945
Blood aluminium increased	38.39	12.02	6	12948	3	31684387
Gastrooesophageal reflux disease	33.41	12.02	54	12900	33817	31650573
Oesophagitis	32.03	12.02	32	12922	12384	31672006
Completed suicide	26.88	12.02	3	12951	91511	31592879
Dysphagia	24.57	12.02	65	12889	57611	31626779
Brugada syndrome	22.11	12.02	9	12945	709	31683681
Vomiting	21.07	12.02	160	12794	223813	31460577
Gastric mucosal calcinosis	20.41	12.02	3	12951	0	31684390
Asthma-chronic obstructive pulmonary disease overlap syndrome	19.75	12.02	9	12945	933	31683457
Toxicity to various agents	18.98	12.02	28	12926	181459	31502931
Off label use	18.00	12.02	77	12877	347197	31337193
Mucosal erosion	17.75	12.02	8	12946	809	31683581
Nausea	16.87	12.02	196	12758	307751	31376639
Decreased appetite	16.43	12.02	113	12841	153104	31531286
Dyspepsia	15.21	12.02	38	12916	32515	31651875
Abdominal pain upper	15.19	12.02	59	12895	63943	31620447
Gastrointestinal pain	15.07	12.02	11	12943	2782	31681608
Blood immunoglobulin E increased	14.87	12.02	10	12944	2221	31682169
Pneumonia	14.38	12.02	204	12750	335108	31349282
Gastritis	14.38	12.02	28	12926	20264	31664126
COVID-19 treatment	14.25	12.02	5	12949	261	31684129
Dehydration	14.06	12.02	90	12864	119021	31565369
Muscle twitching	13.92	12.02	17	12937	8213	31676177
Oesophageal ulcer	13.74	12.02	11	12943	3187	31681203
Fatigue	13.60	12.02	202	12752	335004	31349386
Abdominal pain	13.54	12.02	104	12850	145848	31538542
Asthenia	13.16	12.02	145	12809	224610	31459780
Lymphocytosis	12.90	12.02	9	12945	2120	31682270
Sputum increased	12.84	12.02	9	12945	2136	31682254
Joint dislocation reduction	12.30	12.02	3	12951	42	31684348
Adenocarcinoma gastric	12.06	12.02	7	12947	1201	31683189

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Gastritis	60.47	11.32	85	30574	44506	70853279
Oesophagitis	58.60	11.32	60	30599	22592	70875193
Gastrointestinal haemorrhage	58.12	11.32	160	30499	137248	70760537
Toxicity to various agents	56.87	11.32	49	30610	382123	70515662
Gastrooesophageal reflux disease	55.69	11.32	122	30537	90717	70807068
Cholecystitis chronic	55.65	11.32	40	30619	9336	70888449
Completed suicide	49.75	11.32	18	30641	227117	70670668
Nausea	46.58	11.32	567	30092	851521	70046264
Drug ineffective	45.90	11.32	230	30429	939522	69958263
Blood aluminium increased	42.90	11.32	7	30652	6	70897779
Rheumatoid arthritis	42.67	11.32	38	30621	291767	70606018
Abdominal pain upper	40.93	11.32	179	30480	193423	70704362
Off label use	40.89	11.32	174	30485	742886	70154899
Impaired gastric emptying	39.99	11.32	33	30626	9433	70888352
Vomiting	39.27	11.32	410	30249	592701	70305084
Maternal exposure during pregnancy	38.46	11.32	3	30656	115342	70782443
Abdominal pain	38.27	11.32	266	30393	341861	70555924
Angina bullosa haemorrhagica	36.74	11.32	10	30649	208	70897577
Contraindicated product administered	36.41	11.32	7	30652	134605	70763180
Facial asymmetry	31.10	11.32	12	30647	775	70897010
Drug abuse	30.04	11.32	13	30646	147243	70750542
Gastric ulcer	29.65	11.32	51	30608	31739	70866046
Early satiety	28.82	11.32	13	30646	1244	70896541
Vulval disorder	28.56	11.32	10	30649	490	70897295
Joint swelling	28.27	11.32	41	30618	253170	70644615
Dehydration	27.76	11.32	180	30479	225962	70671823
Dysphagia	27.49	11.32	109	30550	112725	70785060
Haemoglobin decreased	27.48	11.32	167	30492	204992	70692793
Hand deformity	26.83	11.32	3	30656	86479	70811306
Overdose	26.15	11.32	21	30638	169724	70728061
Pericarditis	26.13	11.32	3	30656	84702	70813083
Cholelithiasis	26.12	11.32	61	30598	47279	70850506
Oesophageal stenosis	25.89	11.32	18	30641	3986	70893799
Muscle swelling	23.97	11.32	10	30649	792	70896993
Haematemesis	23.84	11.32	60	30599	48737	70849048
Lower respiratory tract infection	22.64	11.32	10	30649	111903	70785882
Oesophageal ulcer	22.08	11.32	20	30639	6474	70891311
Intentional overdose	21.20	11.32	8	30651	98427	70799358
Drug intolerance	21.07	11.32	41	30618	225646	70672139
Tarsal tunnel syndrome	21.03	11.32	8	30651	497	70897288
Purpura senile	20.94	11.32	8	30651	503	70897282
Systemic lupus erythematosus	20.78	11.32	9	30650	101893	70795892
Infusion related reaction	20.12	11.32	34	30625	197500	70700285
Treatment failure	19.61	11.32	20	30639	144122	70753663
Weight decreased	19.23	11.32	212	30447	310276	70587509
Product dose omission issue	19.17	11.32	160	30499	217308	70680477
Exposure during pregnancy	19.11	11.32	7	30652	87710	70810075
Ulcer haemorrhage	18.98	11.32	16	30643	4709	70893076
Blood alkaline phosphatase increased	18.90	11.32	62	30597	58459	70839326
Gallbladder disorder	18.64	11.32	30	30629	17682	70880103
Biliary dyskinesia	18.42	11.32	12	30647	2387	70895398
Constipation	18.30	11.32	178	30481	252260	70645525
Diarrhoea	18.27	11.32	455	30204	782886	70114899
Brugada syndrome	17.77	11.32	9	30650	1114	70896671
Musculoskeletal stiffness	16.41	11.32	24	30635	147736	70750049
Dyspepsia	16.31	11.32	79	30580	88998	70808787
Psoriatic arthropathy	16.22	11.32	4	30655	64767	70833018
Gastrointestinal pain	16.21	11.32	19	30640	8308	70889477
Therapeutic product effect decreased	16.10	11.32	23	30636	142995	70754790
Hiatus hernia	16.02	11.32	31	30628	21103	70876682
Asthma-chronic obstructive pulmonary disease overlap syndrome	14.98	11.32	9	30650	1555	70896230
Gastric haemorrhage	14.89	11.32	24	30635	14161	70883624
Product use issue	14.86	11.32	35	30624	179902	70717883
Blood potassium decreased	14.66	11.32	46	30613	42375	70855410
Genotype drug resistance test positive	14.43	11.32	8	30651	1188	70896597
General physical health deterioration	14.35	11.32	53	30606	235978	70661807
Movement disorder	14.31	11.32	32	30627	24097	70873688
Hepatic enzyme increased	14.23	11.32	29	30630	156961	70740824
Glossodynia	14.21	11.32	10	30649	86477	70811308
Short-bowel syndrome	14.17	11.32	6	30653	493	70897292
Paranoia	13.90	11.32	26	30633	17262	70880523
Pneumonia	13.77	11.32	346	30313	595886	70301899
Product use in unapproved indication	13.68	11.32	45	30614	207433	70690352
Melaena	13.36	11.32	54	30605	56301	70841484
Resorption bone increased	13.34	11.32	8	30651	1377	70896408
Ocular neoplasm	13.33	11.32	5	30654	299	70897486
Lactic acidosis	12.85	11.32	6	30653	65018	70832767
Asthenia	12.85	11.32	273	30386	457393	70440392
Gastric ulcer haemorrhage	12.69	11.32	17	30642	8501	70889284
Gastric disorder	12.32	11.32	37	30622	33285	70864500
Upper respiratory tract infection	12.21	11.32	67	30592	79207	70818578
Gastrointestinal ulcer haemorrhage	12.16	11.32	7	30652	1117	70896668
Back pain	12.01	11.32	174	30485	270978	70626807
Bezoar	11.80	11.32	9	30650	2297	70895488
Vestibular disorder	11.75	11.32	9	30650	2311	70895474
Drug interaction	11.67	11.32	107	30552	381334	70516451
Cellulitis	11.67	11.32	78	30581	98850	70798935
Blood magnesium decreased	11.53	11.32	22	30637	14819	70882966
Upper gastrointestinal haemorrhage	11.47	11.32	39	30620	37438	70860347
COVID-19 treatment	11.39	11.32	5	30654	449	70897336

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A02BX02	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
FDA CS	M0015420	Organometallic Compounds
MeSH PA	D000897	Anti-Ulcer Agents
MeSH PA	D005765	Gastrointestinal Agents
FDA EPC	N0000175801	Aluminum Complex

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Duodenal ulcer disease	indication	51868009	DOID:1724
Maintenance of Healing Duodenal Ulcer	indication
Gingivostomatitis	off-label use	20607006
Peptic reflux disease	off-label use	57643001
Stomatitis	off-label use	61170000	DOID:9637
Gastroesophageal reflux disease	off-label use	235595009	DOID:8534
Gastric ulcer	off-label use	397825006	DOID:10808
NSAID-Induced Duodenal Ulcer	off-label use
Sclerotherapy Induced Esophageal Ulcer	off-label use
Stress-Related GI Mucosal Bleeding Prevention	off-label use
Maintenance of Healing Gastric Ulcer	off-label use
Prevention of Stress Ulcer	off-label use
Sclerotherapy-Induced Mucositis	off-label use
End stage renal disease	contraindication	46177005	DOID:784
Hyperglycemia	contraindication	80394007	DOID:4195
Aluminum intoxication	contraindication	236546003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1GM/10ML	SUCRALFATE	VISTAPHARM	A211884	March 15, 2022	RX	SUSPENSION	ORAL	Sept. 11, 2022	COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Pepsin A-5	Enzyme	P0DJD9	PEPA5_HUMAN	INHIBITOR				CHEMBL	CHEMBL

External reference:

ID	Source
4018816	VUID
N0000147119	NUI
4018816	VANDF
C0038633	UMLSCUI
CHEBI:9313	CHEBI
CHEMBL3989780	ChEMBL_ID
CHEMBL2367706	ChEMBL_ID
D013392	MESH_DESCRIPTOR_UI
DB00364	DRUGBANK_ID
7055	IUPHAR_LIGAND_ID
2723	INN_ID
XX73205DH5	UNII
10156	RXNORM
1948	MMSL
476	MMSL
5518	MMSL
d00377	MMSL
001132	NDDF
387387008	SNOMEDCT_US
69967001	SNOMEDCT_US
121494085	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2210	TABLET	1 g	ORAL	ANDA	20 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0747	SUSPENSION	1 g	ORAL	NDA	20 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0974	SUSPENSION	1 g	ORAL	ANDA	17 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	0254-1011	SUSPENSION	1 g	ORAL	NDA authorized generic	19 sections
sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-9205	SUSPENSION	1 g	ORAL	ANDA	20 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-4517	TABLET	1 g	ORAL	ANDA	20 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7269	SUSPENSION	1 g	ORAL	ANDA	17 sections
SUCRALFATE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-523	TABLET	1 g	ORAL	ANDA	2 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0062	SUSPENSION	1 g	ORAL	ANDA	18 sections
Carafate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0170	SUSPENSION	1 g	ORAL	NDA	19 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-1011	SUSPENSION	1 g	ORAL	NDA AUTHORIZED GENERIC	19 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-1011	SUSPENSION	1 g	ORAL	NDA AUTHORIZED GENERIC	19 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	29033-003	TABLET	1 g	ORAL	ANDA	18 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-757	TABLET	1 g	ORAL	ANDA	20 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-781	SUSPENSION	1 g	ORAL	ANDA	18 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-781	SUSPENSION	1 g	ORAL	ANDA	18 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	43353-061	TABLET	1 g	ORAL	NDA	18 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0582	TABLET	1 g	ORAL	ANDA	20 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3019	TABLET	1 g	ORAL	ANDA	20 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5287	TABLET	1 g	ORAL	NDA AUTHORIZED GENERIC	18 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	50268-732	SUSPENSION	1 g	ORAL	ANDA	18 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	50268-745	SUSPENSION	1 g	ORAL	ANDA	18 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	51079-753	TABLET	1 g	ORAL	ANDA	20 sections
SUCRALFATE	HUMAN PRESCRIPTION DRUG LABEL	1	51655-031	TABLET	1 g	ORAL	ANDA	9 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	53002-4930	TABLET	1 g	ORAL	ANDA	20 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0593	TABLET	1 g	ORAL	NDA	18 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0797	TABLET	1 g	ORAL	ANDA	18 sections
Carafate	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3735	SUSPENSION	1 g	ORAL	NDA	19 sections
Sucralfate	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3933	TABLET	1 g	ORAL	ANDA	11 sections
SUCRALFATE	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5299	SUSPENSION	1 g	ORAL	NDA	19 sections